Investigational drug · Phase 3
Cyclosporin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Membranous Nephropathy.
Phase 3Last checked: Nov 20, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1,211
Any phase or sponsor naming "Cyclosporin"
First trial start
2024
Jul 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cyclosporin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Membranous Nephropathy
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Cyclosporin" as an intervention, largest first.
- LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical PracticeNot yet recruiting
Fondazione ISIDEAcademic, hospital or other
NCT07336641 · 20,000 participants (planned) · Start Jan 2026 · Primary completion May 2026
Drug: Conventional Systemic Therapies; Biologic Therapies · For: Psoriasis; Atopic Dermatitis; Vitiligo and 2 more
Sites: Rozzano, Italy
PfizerPfizer (PFE)
NCT01646385 · 6,393 participants · Start Feb 2012 · Primary completion Aug 2012
Drug: etanercept; non-biologic anti-rheumatic drugs · For: Rheumatoid Arthritis
University Hospital, AngersGovernment (non-federal)
NCT02416388 · 3,100 participants (planned) · Start Jan 2015 · Primary completion Jul 30, 2025
Drug: Idarubicin; Daunorubicin and 8 more · For: Acute Myeloid Leukemia (AML)
Sites: Amiens, France; Angers, France; Argenteuil, France · 56 sites in all
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their InfantsActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06126835 · 2,828 participants (planned) · Start Aug 26, 2024 · Primary completion May 31, 2031
Drug: Ozanimod; Conventional therapy and 1 more · For: Ulcerative Colitis
Sites: Eden Prairie, Minnesota
- Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate EpisodesPivotal-lookingTerminated
Atrial Fibrillation NetworkAcademic, hospital or other
NCT02618577 · 2,608 participants · Start Feb 2016 · Primary completion Dec 31, 2022
Drug: Edoxaban; ASA · For: Atrial High Rate Episodes
Sites: Multiple Locations, Austria; Multiple Locations, Belgium; Multiple Locations, Bulgaria · 18 sites in all
Fundación Academia Española de DermatologíaAcademic, hospital or other
NCT05674695 · 2,500 participants (planned) · Start Jan 1, 2019 · Primary completion Jan 1, 2029
Drug: Ciclosporin · For: Dermatitis, Atopic
Sites: Badalona, Spain; Alicante, Spain; Barcelona, Spain · 9 sites in all
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
Da, Yuwei, M.D.Individual
NCT04101578 · 2,000 participants (planned) · Start Feb 8, 2017 · Primary completion Jun 1, 2023
Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg) · For: Myasthenia Gravis
Sites: Beijing, China
- Causes of Visual Loss in Retinal DiseaseStatus unknown
Royal Surrey County Hospital NHS Foundation TrustAcademic, hospital or other
NCT01613963 · 2,000 participants (planned) · Start May 2012 · Primary completion Dec 2012
Drug: Immunosuppressive Agents · For: Uveitis; Scleritis
Sites: London, United Kingdom; Guildford, United Kingdom
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A NanoBiT-based high-throughput assay system for monitoring osteoclast fusion.
Yoshino M, Hanahira S, Nakatani M, et al. · Anal Biochem 2027
- Management strategy in aplastic anemia patients with HBV infection following intensive immunosuppressive therapy in Chinese cohort: prophylactic antiviral therapy may not be necessary with close monitoring.
Zhang Y, Chen X, Zhang T, et al. · Hematology 2026
- Calcineurin-mediated regulation of macrophage plasticity drives anti-tumor activity.
Yang R, Chen Y, Liu J, et al. · Mol Ther Adv 2026
- Intensity-dependent microcurrent stimulation enhances BMSC-derived cartilage microtissue formation under defined culture conditions.
Fei X, Wu H, Li M, et al. · Mater Today Bio 2026
- Analytical quality-by-design-guided green RP-HPLC method to quantify cyclosporin A and luteolin simultaneously in a combination of two drug solutions and two drug-loaded next-generation emulsions or nanocapsules.
Das A, Sree A, Chabru AS, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2026
- Genetic mutation patterns in Indonesian children with primary steroid-resistant nephrotic syndrome.
Fahlevi R, Trihono PP, Muktiarti D, et al. · Pediatr Nephrol 2026
Also in development for Primary Membranous Nephropathy
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- B007Phase 33 trials
Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis
- ZuberitamabPhase 32 trials
BioRay Pharmaceutical Co., Ltd. · Primary Membranous Nephropathy
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
- BudoprutugTNT119Phase 23 trials
Climb Bio, Inc. · Primary Membranous Nephropathy, Systemic Lupus Erthematosus, Immune Thrombocytopenia (ITP)
- FKC289Phase 22 trials
Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Primary Membranous Nephropathy, Primary Light Chain (AL) Amyloidosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.